Company ProfilePremium

Botanix Pharmaceuticals Limited

Company Profile Analysis

Ticker: BOT.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Botanix Pharmaceuticals Limited - Company showcase

Year Founded & Workforce

1984

Botanix Pharmaceuticals Limited logo

Botanix Pharmaceuticals Limited Employee Contacts

3 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Botanix Pharmaceuticals Limited Overview

Botanix Pharmaceuticals is an ASX-listed, US-operated, single-product commercial dermatology company. Its sole marketed asset, Sofdra (sofpironium) topical gel 12.45%, is the first and only new chemical entity approved by the US FDA for primary axillary hyperhidrosis — an underserved condition the company sizes at roughly 10 million US patients, of whom about 3.7 million actively seek treatment. Botanix acquired global rights to sofpironium bromide from Brickell Biotech in 2022, secured FDA approval in June 2024, and launched nationally with a field sales force in February 2025. The commercial model pairs a dermatology-focused sales team with a proprietary closed-loop fulfilment platform (single specialty pharmacy, direct-to-patient shipping, prior-authorisation support) that bypasses wholesalers. FY26 net revenue reached A$33.8 million on A$152.8 million gross sales, but losses, a deeply discounted 2026 equity raise, a going-concern material uncertainty and a ~94% share-price decline since mid-2025 frame Botanix today as a high-growth, capital-constrained micro-cap.


Company's own description (FY26 Annual Report, paraphrased)

In its FY26 Directors' Report, Botanix characterises itself as a revenue-generating pharmaceutical company with an FDA-approved product, accelerating commercial traction, a proven fulfilment platform, and the infrastructure required for continued expansion. It positions Sofdra as a novel, safe and effective solution for primary axillary hyperhidrosis, citing its mechanism (blocking acetylcholine at the M3 receptor in the sweat gland), its rapid metabolism (designed to reduce systemic anticholinergic adverse events), and its proprietary applicator, which limits drug contact with the hands. It describes hyperhidrosis as the third-largest dermatologic condition in the US after acne and atopic dermatitis, and states that FY26 marked its transition from a development-stage biotechnology company to a revenue-generating commercial pharmaceutical business.

What the company does

Botanix in-licensed and now commercialises a single topical anticholinergic, Sofdra, in the United States. It does not manufacture: active pharmaceutical ingredient (API) is currently sourced from Kaken Pharmaceutical (Japan), finished goods are made at a contract manufacturing site in Canada, and dispensing occurs through a single specialty pharmacy network (identified in company footnotes as SendRx). Botanix's own value-add is commercial: sales force promotion to dermatologists, payer contracting, patient services, prior authorisation support, co-pay buy-down, refill management and marketing.

Business and revenue model

Revenue streamMechanismFY26 contribution (AUD)Source
Sofdra net product sales (US)Product shipped to patients against prescriptions via the Botanix Fulfilment Platform; revenue recognised at delivery, net of rebates, chargebacks, co-pay support and government program deductions (gross-to-net)33,219,460FY26 AR, Note 3
Net royalties (Japan / South Korea)Royalties received from Kaken Pharmaceutical on Ecclock (sofpironium bromide gel 5%) in Japan and via Kaken's South Korean sublicensee Dongwha Pharm; presented net of royalties Botanix must pay onward under the sofpironium asset purchase agreement (Botanix acts as agent)582,046 (1,293,437 received less 711,391 paid)FY26 AR, Note 3
Services / subscription / licensing upfrontsNone recognised in FY260FY26 AR, Note 3

Mix for FY26: ~98.3% product, ~1.7% net royalty/licensing; 0% services or subscriptions. Revenue is entirely "goods transferred at a point in time".

Value-chain position

Botanix sits at the brand-owner/commercialiser layer of the specialty pharmaceutical value chain: IP owner and NDA holder, outsourcing chemistry (API), formulation and fill-finish to third parties, and outsourcing dispensing to a partner pharmacy while retaining control of the patient journey and data. Removing the wholesaler and consigning inventory directly to the pharmacy is presented by the company as a source of supply-chain cost savings and real-time data visibility (FY25 and FY26 Annual Reports).

Customer types and end-markets

StakeholderRoleNotes
Patients with primary axillary hyperhidrosis (age 9+)End user~10 million US patients; ~3.7 million actively seeking treatment (company estimate, adapted from 2019 Cowen analysis)
Dermatologists, PAs and NPsPrescribersUnique prescribers grew from 1,075 (Q3 FY25 exit) to 2,316 (Q4 FY25 exit); later counts not disclosed
Commercial payers / PBMs, Medicare Part D, MedicaidReimbursementPayer contracts require confirmation of diagnosis and, for some, prior trial of aluminium chloride (FY25 AR)
Specialty pharmacy (SendRx)Dispensing partnerSingle pharmacy network under the Botanix Fulfilment Platform
Kaken Pharmaceutical / Dongwha PharmLicensee / sublicenseeRoyalty-paying partners in Japan and South Korea; Kaken is also current API supplier

End-market: US prescription medical dermatology (hyperhidrosis segment); secondary exposure to Japanese and Korean hyperhidrosis markets via royalties.

Independent characterisation

Botanix is best understood as a single-asset US specialty pharma launch vehicle funded from the Australian equity market. Its operating metrics show genuine product-market traction — FY26 prescriptions shipped rose 527% to 105,794 and Q4 FY26 set a monthly record of 12,895 shipments — but the economics are dominated by a very low net-to-gross realisation (average gross-to-net "yield" of 22% in FY26, meaning roughly A$0.22 of net revenue per A$1 of gross sales), heavy promotional spend (A$52.0M product sales and marketing expense in FY26 versus A$33.8M of revenue), and dependence on a single API source in Japan. The investment case therefore rests on three levers: (i) improving gross-to-net toward the 30–40% management target, (ii) reducing cost of goods via the second API supplier (Piramal), and (iii) leveraging the fulfilment platform with additional in-licensed or acquired products. The balance-sheet position — A$36.6M cash against A$24.9M of secured Kreos debt at fair value and an auditor-noted material uncertainty on going concern — means execution must occur against a short funding runway.

Strategy

Stated strategic themes (FY26 Annual Report, paraphrased)

Management lists its priorities as: (1) continuing growth of the Sofdra franchise and commercial momentum; (2) exploring acquisitions that could leverage Botanix's sales force and fulfilment capability; (3) engaging with inbound licensing and acquisition interest; (4) strengthening the Sofdra IP estate; (5) onboarding Piramal as an alternate API supplier for resilience and long-term margin; (6) improving cash flow and working-capital management; (7) optimising resource allocation and sales-force alignment for efficiency and profitability; and (8) validating that the fulfilment platform can support additional products. The overarching message is a pivot from "accelerate the launch" (FY25) to "disciplined, sustainable growth toward profitability" (FY26).

Initiative register — last 24 months

DateInitiativeTypeTarget / outcomeStatus
Dec 2024Patient Experience Program with International Hyperhidrosis SocietyLaunchValidate telehealth + fulfilment; first revenueCompleted
Dec 2024First payer contractsMarket accessCoverage with diagnosis / prior aluminium chloride stepCompleted
Feb 2025National launch with 27 sales professionalsCommercialFirst full quarter TRx 13,647 (Q4 FY25)Completed
Q4 FY25–Oct 2025Sales force expansion 27→33→50CommercialFunded mainly by reallocating sales & marketing budgetCompleted; later reversed in part
Jun 2025Kreos US$30M debt facilityFinancingWorking capital, platform expansionTranche A drawn; Tranche B status after 1 Oct 2026 not disclosed
FY25–FY26Spanish-language patient materialsMarketingReach ~41M US Spanish speakersIn development (FY25 AR)
FY25–FY26Medical education: JAAD publication, Fall Clinical, AAD Innovation Academy posters; speaker programme; "Summer of Sweat" HCP events; Hyperhidrosis Awareness Month supportMedical affairsPhysician adoptionOngoing
Feb 2026A$45M equity raiseFinancingAPI purchases, second supplier, marketing, working capitalCompleted (EGM 1 Apr 2026)
Mar 2026Kaken API agreement renegotiationSupply / cashDefer ~A$15M of purchases; no API purchase before Dec 2027Completed
Apr 2026Piramal second API supplierSupply / margin / tariff25–40% lower long-term COGS; US site; onboarding complete 2028In progress
Jul 2026EPO intention to grant (applicator) and US Notice of Allowance (drug substance)IPProtection to 2039/2040Pending formal grant/issue
31 Jul 2026Sales force resizing 50→39Cost programme~12% lower operating costs; 94% coverage retainedImplemented
OngoingPlatform product acquisition / in-licensingBusiness developmentAdd revenue-accretive dermatology productNo transaction announced
OngoingEx-Asia sublicensing of sofpironium (e.g., Europe)LicensingUpfronts, milestones, royaltiesNo transaction announced

ESG commitments: none formal; the company has committed to develop an ESG framework in future (FY25 and FY26 ARs).

Medium-term targets and guidance

ItemGuidanceSource
Gross-to-net yieldTarget average 30–40% over time; GTN expected to continue rising through 1H FY27FY25 AR; Q2 FY26 4C; FY26 AR
RevenueExpected to rise quarter on quarterFY26 AR (going concern discussion)
Operating costs~12% reduction from 31 Jul 2026FY26 AR
API purchasesNone expected before December 2027FY26 AR
COGS25–40% long-term reduction once Piramal onboarded (2028)FY26 AR
Profitability"Clear path to profitability" asserted (FY25 AR, Q2 FY26 4C); no date or quantified EBITDA target given—
Revenue / earnings guidanceNo numerical revenue or EBITDA guidance—

Products & Services

Marketed product: Sofdra (sofpironium) topical gel, 12.45%

AttributeDetail
IndicationPrimary axillary hyperhidrosis (excessive underarm sweating) in adults and children aged 9 years and older
Regulatory statusFDA-approved 18 June 2024 (NDA); first and only NCE approved by FDA for this indication
MechanismAnticholinergic; targets M3 muscarinic receptor in eccrine sweat glands, blocking acetylcholine signalling to reduce sweat at source; designed as a "soft" drug rapidly metabolised once systemically absorbed
Formulation / deviceTopical gel dispensed via proprietary pump bottle with applicator that avoids hand contact (applicator subject of the 2026 EPO intention to grant)
Clinical basisTwo pivotal Phase 3 CARDIGAN studies (>700 patients) met all primary and secondary endpoints at day 43 (Gravimetric Sweat Production and HDSM-Ax-7 patient-reported severity); ~300 patients in a separate 48-week safety study; most adverse events mild-to-moderate and transient; Phase 3 data published in the Journal of the American Academy of Dermatology, vol. 93, July 2025
Key safety label pointsContraindicated in glaucoma, severe ulcerative colitis, myasthenia gravis, Sjögren's syndrome; warnings for blurred vision and urinary retention; common AEs include dry mouth, blurred vision, application-site reactions, mydriasis, urinary problems; product is flammable
Target customerUS dermatologists, dermatology PAs/NPs; patients with confirmed PAH, typically after trying aluminium chloride (payer step)
LaunchEarly-access Patient Experience Program Dec 2024; full national launch with sales force February 2025
Pricing modelWholesale acquisition cost not disclosed in sources reviewed. Derived economics for FY26: gross sales of ~A$1,444 per prescription shipped and net revenue of ~A$314 per prescription (A$152.8M and A$33.2M over 105,794 TRx)
ChannelBotanix Fulfilment Platform (single specialty pharmacy, direct-to-home shipping, auto-refill, PA support, co-pay buy-down); wholesaler removed
AdherencePatients averaged more than 5 fills (FY26 AR) vs an industry average of fewer than 2 fills per year for topicals; 95% adherence among auto-refill enrolees and 79% overall (FY25 AR)
Patent lifeExisting patents plus European applicator patent (expected to May 2039) and US crystalline-form drug-substance patent (expected to May 2040) once issued
Physician sentimentMay 2026 survey of 21 US dermatology HCPs: 100% expect to maintain or increase prescribing; earlier Q2 FY26 survey: 90% expected to increase prescribing

Licensed-out product: Ecclock gel 5% (sofpironium bromide)

AttributeDetail
Territory / partnerJapan — Kaken Pharmaceutical (licensee inherited via Brickell); South Korea — Dongwha Pharm (Kaken sublicensee)
StatusMarketed in Japan since 2020; approved in South Korea August 2025 and launched January 2026
Economics to BotanixRoyalties received (A$1.29M FY26) net of royalties paid onward (A$0.71M FY26); Botanix expects minimal revenue from the Korean sublicense
Strategic noteBotanix retains the right to sublicense sofpironium bromide outside Asia, with potential upfronts, milestones and royalties

Platform / service capability: Botanix Fulfilment Platform

AttributeDetail
DescriptionClosed-loop prescription fulfilment: single specialty pharmacy network, dedicated support team for prior authorisation, co-pay management, direct-to-patient shipment, personal refill follow-up, real-time data feed to Botanix
LaunchFully developed and tested before December 2024 Patient Experience Program
MonetisationNot a separately priced service; drives GTN and refill economics. Company is assessing acquisition opportunities where the platform could improve another product's GTN and refill rate
Telehealth componentDigital telehealth platform for diagnosis of hyperhidrosis deployed (FY25); certain executive incentive tranches tied to telehealth-derived revenue remain unvested at FY26

Legacy development pipeline

Pre-2022 programmes (Permetrex-based synthetic cannabidiol topicals BTX 1503, BTX 1204, BTX 1308; antimicrobial BTX 1801) are no longer referenced in the FY25 or FY26 Annual Reports' principal activities. FY26 reported zero research expense (FY25: A$0.14M), confirming that internal R&D has effectively ceased. Their current status is not publicly disclosed in the sources reviewed; the analyst treats them as discontinued or dormant.

Lifecycle and business development

The FY26 STI scorecard rewarded management for generating at least one feasible Sofdra lifecycle-extension concept (achieved) but the target of a signed term sheet for a late-stage or marketed product was not achieved (0%). No new product has been added as of the report date.

Financial Narrative

All figures A$ millions unless stated; fiscal years end 30 June.

Income statement

Notes and discrepancies:

  • FY22 and FY23 "net income" values are those shown in the remuneration report's five-year table, which labels them "loss for the year attributable to owners"; for FY24 the same table shows A$13.71M, which equals total comprehensive loss rather than the A$13.87M statutory loss after tax. FY22–FY23 figures may therefore also be comprehensive-loss figures.

  • The FY25 Appendix 4E states the FY24 comparative "loss from ordinary activities after tax" as A$32.03M, which conflicts with the A$13.87M in the FY25 audited income statement. The audited statement is preferred; the discrepancy is unexplained in the documents reviewed.

  • EBIT derived as loss before tax plus finance expenses less interest income. FY25 EBIT includes a one-off A$5.11M cost of issuing debt (Kreos); FY26 includes a A$1.59M gain on fair-value movement of the Kreos liability.

  • Gross profit is a proxy: "materials and related expenses" is the closest line to COGS; Botanix does not present a gross profit subtotal.

Margins and growth (derived)

Revenue CAGR FY23–FY26 (3-year, derived): ~590% p.a., from A$0.10M to A$33.8M. A five-year CAGR is undefined because FY22 revenue was nil.

Commentary. The key inflection is FY25→FY26: revenue rose 5.9x while total operating expenses rose only ~11% (A$94.1M to A$104.8M), so the operating margin improved from -1,529% to -201%. Gross margin proxy improved to 57.6% as volume absorbed fixed manufacturing costs, though it remains depressed relative to mature branded dermatology (Journey Medical reported 66.2% for CY2025) because net price realisation is so low: at a 22% GTN yield, materials cost per unit consumes a much larger share of net revenue than it would at the 30–40% GTN management targets. Share-based payments halved to A$10.4M, contributing ~A$10M of the A$16.6M year-on-year reduction in net loss. Product sales and marketing (A$52.0M) remains the dominant cost and exceeded revenue by 1.5x in FY26. The post-balance-date sales-force resizing (~12% cost reduction from 31 July 2026) and deferral of API purchases are the principal levers for FY27 loss reduction.

Balance sheet (as at 30 June)

Sources: FY25 AR (FY24 comparatives; FY23 cash and opening equity from cash flow and equity statements); FY26 AR. Debt is the Kreos loan carried as "financial liabilities at fair value through profit or loss".

Commentary. Net cash has fallen from A$79.3M (FY24) to A$10.9M (FY26). Inventory has become a major use of capital (A$31.4M, of which A$19.3M raw materials, essentially pre-purchased API), equal to 86% of year-end cash. Intangibles comprise only the sofpironium licence, amortised straight-line over ~16 years. Equity has been eroded by losses (accumulated losses A$247.0M at FY26) despite A$79.9M of new contributed equity across FY25–FY26.

Cash flow

Note: the December 2025 cancellation of 6,928,586 erroneously issued shares was a nil-consideration buy-back with no cash outflow.

Commentary. FY26 operating cash burn of A$64.6M improved 18% year on year, and the quarterly trajectory is more informative: A$28.4M (Q4 FY25, inflated by A$11.2M inventory), A$13.1M (Q1 FY26), A$17.2M (Q2), A$23.3M (Q3, incl. A$9.7M API purchase) and A$10.6M (Q4). Stripping the API purchase, Q3 underlying burn was ~A$13.6M. With no API purchases expected before December 2027 and the sales-force resizing, a sub-A$10M quarterly burn in FY27 is plausible but not guided; quarter-end cash of A$36.6M equates to roughly 3–4 quarters at Q4 FY26 burn rates, which explains the going-concern material uncertainty.

Ratios (derived)

Not meaningful: net debt/EBITDA (net cash, negative EBITDA); interest coverage (EBIT of -A$68.0M vs finance expense of A$2.8M = -24x); cash conversion cycle (inventory days distorted by multi-year API stockpile; payables include marketing accruals).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Per-Share Data

Metric (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Revenue

00.100.605.7633.80

Materials and related expenses (COGS proxy)

——03.4414.33

Gross profit (revenue less materials; derived)

——0.602.3219.47

Product sales and marketing expense

——038.4652.01

Employee and related expenses

——2.7012.5114.17

Share-based payments expense

——4.3920.5210.41

Research expenses

——1.810.140

Depreciation and amortisation

——0.072.262.32

Operating income / EBIT (derived)

——-13.93-88.02-68.04

EBITDA (derived)

——-13.86-85.76-65.72

Pre-tax income

——-13.87-86.40-69.77

Net income (statutory loss after tax)

-12.98-8.92-13.87-86.40-69.77

EPS basic (A$ cents)

-1.35-0.79-0.92-4.68-3.22

EPS diluted (A$ cents)

-1.35-0.79-0.92-4.68-3.22

Dividends per share (A$ cents)

00000

Margin Analysis (%)

Metric (%)FY2024FY2025FY2026

Gross margin (proxy)

100.040.357.6

Operating margin

-2,314-1,529-201

EBITDA margin

-2,302-1,490-194

Net margin

-2,304-1,501-206

Revenue growth YoY

485857487

Balance Sheet and Per-Share Data

Metric (AUD Mn)FY2023FY2024FY2025FY2026

Total assets

—112.46129.10105.98

Cash and cash equivalents

10.2579.3164.9736.63

Inventory

—1.2128.0831.35

Trade and other receivables

—0.823.206.64

Intangible assets (sofpironium licences)

—29.4928.1224.88

Goodwill

—000

Short-term debt (Kreos, fair value)

—08.8213.82

Long-term debt (Kreos, fair value)

—022.0711.03

Total debt excl. leases

—030.8924.85

Lease liabilities

—01.220.92

Net debt (negative = net cash; incl. leases)

—-79.31-32.86-10.86

Total liabilities

—3.7347.8042.45

Total equity

22.95108.7381.3063.52

Working capital

—79.1774.6749.30

Net tangible assets per share (A$ cents)

—4.382.711.41

Cash Flow

Metric (AUD Mn)FY2023FY2024FY2025FY2026

Receipts from customers

—1.063.9530.96

Operating cash flow

—-8.13-78.58-64.60

Capex (plant and equipment)

—-0.11-0.290

Payments for intangibles

—-17.89-0.760

Free cash flow (OCF less capex; derived)

—-8.24-78.87-64.60

Free cash flow incl. intangibles (derived)

—-26.13-79.63-64.60

Equity issued (gross proceeds)

—100.8540.4645.02

Debt drawn (Kreos convertible loan)

—028.400

Debt repaid

—00-2.76

Dividends paid

0000

Share buybacks (cash)

0000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2024FY2025FY2026

ROE (%) — loss / average equity

—-90.9-96.4

ROA (%) — loss / average total assets

—-71.5-59.4

ROIC (%) — EBIT / (equity + debt + leases − cash)

—-181.7-129.2

Current ratio (x)

22.24.02.6

Debt / equity (x)

00.380.39

Asset turnover (x) — revenue / average total assets

—0.050.29

Days sales outstanding (days, trade receivables / revenue)

—18164

Days inventory (days, inventory / materials expense)

—2,980799

Revenue by Region

Region (AUD Mn)FY2024FY2025FY2026

United States — Sofdra net sales

05.0933.22

Japan and South Korea — net royalties

0.600.660.58

Europe / rest of world

000

Total

0.605.7633.80

Region growth (%)

Region growth (%)FY2025FY2026

United States (Sofdra)

—552

Japan / South Korea (net royalties)

10.2-12.2

Share Price

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

0.060.130.350.320.019

Performance Window Details

Performance window (approx., to late Sep 2026 at ~A$0.019)Change

1 year (vs ~A$0.12–0.145 in Aug–Oct 2025)

approx. -85% to -87%

3 years (vs A$0.13 at 30 Jun 2023)

approx. -85%

5 years (vs A$0.08 at 30 Jun 2021)

approx. -76%

52-week range

A$0.018 – A$0.18 (Stocklight)

Largest single-day move

-41.3% on 17 Feb 2026 (A$45M raise at A$0.06)

Valuation Snapshot

MultipleValueBasis

Market capitalisation

~A$51M

—

Enterprise value

~A$40M

Market cap less FY26 net cash of A$10.9M (incl. leases)

EV / Sales (FY26)

~1.2x

EV / A$33.8M

EV / Gross sales (FY26)

~0.26x

EV / A$152.8M

P / Book

~0.8x

Market cap / A$63.5M equity

Source Details

SourceRating / targetComment

Eulerpool (aggregated consensus, Aug 2026)

12-month target A$0.42

~20x current price; likely includes stale targets

TipRanks (latest listed rating)

Buy, A$2.00 target

Appears to predate the February 2026 raise; conflicts with Eulerpool consensus — discrepancy flagged

TradingView (early 2026)

Range A$0.24–2.00

Pre-raise

Investing.com consensus (via Parqet, Apr 2026)

Revenue 27.71M (2026) and 56.43M (2027); EPS -0.02 (2026), -0.01 (2027)

Currency labelled USD by aggregator; FY26 actual (A$33.8M) exceeded the 2026 figure

Capital Markets

ItemDetail

Dividend policy / history

No dividends ever paid or declared

Buybacks

None for value; nil-consideration cancellation of 6.93M shares (Dec 2025)

Options outstanding

840,747,200, including 772,997,200 placement options at A$0.06 (table shows expiry 20 Apr 2029; the Directors' Report narrative states 31 Jan 2027 — discrepancy in the FY26 AR)

Performance rights outstanding

96,183,332

Warrants

3,030,303 (Kreos) at A$0.33, expiring 10 Jun 2030

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt

Kreos Capital VII secured facility: US$20M drawn June 2025 (Tranche A); US$10M Tranche B available to 1 Oct 2026 subject to conditions; part convertible at lender's option; financial, corporate and operating covenants including minimum cash. Carrying value at fair value A$24.85M (current A$13.82M; non-current A$11.03M) at 30 Jun 2026; A$2.76M principal repaid in FY26

Debt maturity profile

~A$13.8M classified as due within 12 months; ~A$11.0M beyond 12 months.

Analyst Conclusions

Management guidance (FY26 AR and Q4 FY26 report)

  • Net revenue expected to rise quarter on quarter.

  • GTN expected to continue rising through 1H FY27 toward a 30–40% long-term target.

  • Operating costs ~12% lower from 31 July 2026 after territory consolidation, with 94% physician coverage retained.

  • No API purchases before December 2027; Piramal onboarding complete in 2028 with 25–40% lower long-term COGS.

  • 15% tariff (~US$10 per bottle) from 29 September 2026.

  • Active evaluation of product acquisitions and inbound licensing/acquisition interest.

  • No numerical revenue, EBITDA or breakeven guidance.

Consensus expectations

Aggregated consensus (Investing.com via Parqet) pointed to roughly a doubling of revenue into the following year (27.71M to 56.43M), with losses narrowing. These figures predate the FY26 result and should be treated as indicative only.

Bull case

  1. Volume plus price compounding: Q4 FY26 TRx of 33,358 annualises to ~133,000; if GTN reaches 30% on stable gross price per script (~A$1,400), annualised net revenue would be ~A$56M (derived), with further upside from new prescribers in retained territories.

  2. Margin structure improving fast: sales-force cut (~12% opex), no API cash outflow until December 2027 and the Piramal COGS reduction could bring quarterly operating cash burn close to breakeven within FY27–FY28, without further equity if Q4 FY26 trends persist.

  3. Asset value exceeds market value: at an EV of ~A$40M (~0.26x gross sales) for an FDA-approved NCE with IP to 2040 and an operating US platform, a strategic acquirer or ex-US licensee could crystallise value well above the current price, consistent with management's track record of dermatology exits.

Bear case

  1. Funding gap: A$36.6M cash, ~A$13.8M of Kreos debt classified as current, and a going-concern material uncertainty suggest another raise is likely within 12 months — probably at or below the current ~A$0.019, implying significant further dilution on top of ~773M A$0.06 options.

  2. Unit economics may not converge: GTN has oscillated between 18% and 24% for five quarters; if payer mix and co-pay costs keep yields near 20%, gross margin and marketing efficiency may never support profitability on a single product.

  3. Governance and policy overhangs: a potential second strike and board spill at the 2026 AGM, tariffs that add ~US$10 per bottle, and US drug-pricing uncertainty could constrain management bandwidth and deter strategic partners.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhat to watch
Late Oct 2026Q1 FY27 Quarterly Activity Report / Appendix 4CTRx growth post-territory cuts; GTN vs 22%; operating outflow vs A$10.6M; cash vs A$36.6M
Oct 2026Kreos Tranche B outcomeWhether US$10M was drawn, lapsed or renegotiated
~Nov 20262026 AGMRemuneration vote (second strike → spill resolution); new independent director appointments
2H CY2026Tariff impactCOGS per unit after 29 Sep 2026
FY27Capital raising / refinancingSize, price, structure (equity vs debt restructure)
FY27US patent issuance and EPO grant/validationFormal completion of July 2026 allowances
FY27Business developmentProduct acquisition, ex-Asia licence, or corporate approach
Q3 FY27 (Jan–Mar 2027)Deductible-reset seasonalityMagnitude of GTN dip vs Q3 FY26 (18%)
2027–2028Piramal onboarding progressRegulatory filing for second API source; COGS trajectory

Analyst verdict

Botanix has done the hard part that most ASX-listed biotechnology companies never achieve: it took an in-licensed molecule through FDA approval, built a US commercial organisation from fewer than ten people, and in its first full year generated A$152.8 million of gross sales and A$33.8 million of net revenue from more than 105,000 prescriptions. Clinical differentiation, physician enthusiasm and exceptional refill behaviour are all documented in the filings. The product is working.

The business model, however, is not yet working. Net realisation of roughly 22 cents per gross sales dollar, promotional spend exceeding revenue by half, and a materials line that still consumes over 40% of net revenue leave the company dependent on external capital. That dependence has been punished: the February 2026 raise at a 45.5% discount reset the share price, which has since fallen to around two cents, and the FY26 accounts carry a going-concern material uncertainty alongside a secured, covenant-bearing Kreos loan. Governance has added friction, with a 74% vote against remuneration, a non-majority-independent board, gross-revenue-based incentive hurdles and administrative errors.

The investment question is therefore one of runway versus inflection. Management has pulled the right levers — deferring API purchases, resizing the sales force toward its 39 productive territories, securing a lower-cost US-based API source and extending patent protection to 2040 — and Q4 FY26 delivered the best combination yet of revenue growth (+45% QoQ) and burn reduction (A$10.6 million). If Q1–Q2 FY27 demonstrate continued script growth with GTN trending toward 25–30% and quarterly burn below A$10 million, the current enterprise value of roughly A$40 million (about 1.2x net and 0.26x gross sales) materially undervalues an approved NCE with a functioning US platform, and a strategic transaction becomes credible. If GTN stalls and another deeply dilutive raise is required, equity holders will continue to fund the gap at punitive prices. On balance, Botanix is a high-risk, binary special situation: operationally promising, financially fragile, and governance-sensitive.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundCommitteesIndependence (analyst view)

Vincent Ippolito

Executive Chairman

18 Jul 2019

40 years in pharma (30+ in dermatology). President & COO, Dermavant Sciences; CCO & EVP, Anacor (sold to Pfizer, US$5.2bn); CCO and other senior roles at Medicis (sold to Valeant, US$2.6bn, 2012); 17 years at Novartis (last role VP Dermatology, Paediatric & Respiratory)

—

Not independent (executive)

Dr William (Bill) Bosch

Non-executive Director

1 Jul 2016 (exec); NED from 1 Jul 2023

30+ years pharma R&D; CSO of iCeutica (SoluMatrix technology, four FDA-approved products); co-founder NanoSystems LLC and co-inventor of NanoCrystal technology (seven FDA-approved products)

Remuneration & Nomination (member)

Questionable: former executive and paid consultant until Oct 2024

Dr Stewart Washer

Non-executive Director

21 Feb 2019

Former exec chair Emyria; chair Orthocell; founding chair Cynata; chaired Hatchtech (sold for A$279M, 2015); former director iCeutica and AusBiotech

Chair, Remuneration & Nomination; member, Audit & Risk

Independent

Danny Sharp

Non-executive Director

22 Mar 2022

30+ years investment banking; Corporate Finance Executive Director at Canaccord Genuity (8 yrs); formerly Shaw and Partners, Lodge Partners; NED of Alcidion Group; CFA; B.Econ/Law

Chair, Audit & Risk; member, Remuneration & Nomination

Independent

Dr Patricia Walker, MD PhD

Non-executive Director

25 Aug 2025

Practising dermatologist; former President & head of R&D at Brickell Biotech; CMO Kythera; EVP & CSO Allergan Medical Aesthetics; former Botanix Chief Medical Advisor

Audit & Risk (member from 26 Feb 2026)

Questionable: former paid adviser to Botanix and to the sofpironium vendor

Executive Leadership Team

NameTitleAppointedPrior roles / education

Dr Howard (Howie) McKibbon

Chief Executive Officer

CEO 24 Aug 2023 (COO from Oct 2022)

SVP Sales & Marketing, Anacor; SVP Worldwide Commercial Operations, Dermavant; VP Dermatology & Immunology, Medicis; launched 15 products (11 dermatology). BA History (University of South Florida), MBA (Mercer University Stetson School), PharmD (Mercer Southern School of Pharmacy). Five-year contract

Chris Lesovitz

Chief Financial Officer — USA

4 Aug 2024

Former CFO, Strata Skin Sciences; 20+ years healthcare/technology finance. Three-year contract

Graeme Morissey

Chief Financial Officer — Australia

26 Mar 2024

18+ years incl. Grant Thornton (Canada, Australia), KPMG, EY; multiple ASX CFO roles; CA ANZ. Contractor at A$125,000 p.a.

Paul Seaback

Chief Operating Officer

COO from Q4 FY26 (announced 3 May 2026); joined Nov 2024 as CTO

30+ years; CTO at Dermavant until its acquisition by Organon; roles at Gilead, Medicis, Hospira, Mayne, Novartis (Sandoz)

Andrew Bickley

Company Secretary

13 Oct 2025

15+ years governance; LLB (University of Essex); FGIA, FCG; also CoSec of Group 6 Metals

Directors' Remuneration

KMPSalary/feesCash bonusOther short-term (insurance + leave)Super/401kOptions (SBP)Performance rights (SBP)Total% performance-based

V. Ippolito (Exec Chair)

683,095225,42086,09415,76701,021,5952,031,97161.4

Dr H. McKibbon (CEO)

667,915154,28782,24115,76601,060,7481,980,95761.3

C. Lesovitz (CFO US)

495,200162,00986,05216,239340,430448,7291,548,65961.4

G. Morissey (CFO AU)

125,00000020,0020145,00213.8

Dr W. Bosch (NED)

85,0000000220,485305,48572.2

Dr S. Washer (NED)

100,0000000220,485320,48568.8

D. Sharp (NED)

100,0000000220,485320,48568.8

Dr P. Walker (NED, part-year)

74,375000247,5170321,89276.9

Total KMP

2,330,585541,716254,38747,772607,9493,192,5276,974,93662.3

Major Shareholders

Holder categoryHoldingSource

Substantial holders (≥5%)

None reported as of 18 August 2026

FY26 AR (ASX additional information, per InvestSMART summary)

Directors and KMP (30 June 2026)

72,302,209 ordinary shares in aggregate (≈2.7% of an implied ~2.7bn shares; derived)

FY26 AR

Largest individual insider holdings

Bosch 21.50M; McKibbon 18.07M; Ippolito 16.67M; Washer 7.83M (indirect); Sharp 6.08M (indirect)

FY26 AR

Index inclusion

Held by S&P/ASX Small Ordinaries ETFs historically; S&P DJI March 2026 quarterly rebalance announcement listed in BOT filings (index deletion likely but not confirmed in sources reviewed)

TradingView; Stocklight

Kreos Capital

3,030,303 warrants at A$0.33 expiring 10 Jun 2030

FY26 AR

Competitive Landscape

Key Competitors

#CompetitorProduct / modalityPositioning vs Sofdra
1

AbbVie

Botox (onabotulinumtoxinA) intradermal injections for severe axillary hyperhidrosis

Highly effective, long-lasting (months), but painful, in-office procedure with prior-authorisation hurdles; Sofdra positioned as non-invasive at-home option

2

Journey Medical Corp (NASDAQ: DERM)

Qbrexza (glycopyrronium tosylate 2.4% cloth) — the only other FDA-approved topical Rx anticholinergic for PAH

Closest direct competitor; Q2 CY2025 Qbrexza revenue ~US$6.9M per CFO commentary

3

Person & Covey and generic makers

Rx aluminium chloride hexahydrate (Drysol and generics)

First-line, cheap; payers often require trial before Sofdra — functions as both competitor and gatekeeper

4

Generic manufacturers

Oral glycopyrrolate / oxybutynin (off-label)

Low cost; systemic anticholinergic side effects

5—

Microwave thermolysis device destroying sweat glands

Durable, procedure-based, cash-pay; complementary niche

6

Candesant Biomedical

Brella SweatControl patch (thermal, in-office)

Newer device option

7

Iontophoresis device makers (e.g., Dermadry, Hidrex, RA Fischer)

Tap-water iontophoresis

Mainly palmar/plantar; home use, time-intensive

8

Unilever, P&G, Church & Dwight and others

OTC "clinical strength" antiperspirants

Mass-market first step; compete for mild sufferers

9

Surgical providers

Endoscopic thoracic sympathectomy, local excision

Last resort; compensatory sweating risk

10

Maruho (Japan)

Rapifort wipes (glycopyrronium tosylate)

—

Peer Comparison FY2026

MetricBotanix (FY26, A$)Journey Medical (CY2025, US$)Qbrexza (within Journey)

Revenue

33.8M

61.9M

Not separately reported annually; ~US$6.9M in Q2 CY2025 (CFO comment)

Revenue growth

+487%+10%

Prescriptions +15% YoY in Mar–Apr 2025 (company commentary)

Gross margin

~57.6% (proxy, derived)

66.2%—

SG&A / sales & marketing

A$52.0M sales & marketing (154% of revenue)

US$44.4M SG&A (72% of revenue)

—

Profitability

EBITDA -A$65.7M (derived)

Adjusted EBITDA +US$2.9M

—

R&D intensity

0%——

Company Snapshot

$21.8M

Revenue

1984

Founded

Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • First-in-class approval: Sofdra is the only FDA-approved NCE for primary axillary hyperhidrosis (approved 18 Jun 2024; one of 32 NCEs approved in 2024) — FY26 AR.
  • Demonstrated demand growth: FY26 TRx up 527% to 105,794; Q4 FY26 TRx 33,358 (+145% YoY); record month June 2026 at 12,895 — FY26 AR, Q4 FY26 4C.
  • Exceptional adherence: average >5 fills per patient vs <2 industry norm; 95% adherence in auto-refill — FY25/FY26 ARs.
  • Physician advocacy: 100% of surveyed HCPs (May 2026) expect to maintain or increase prescribing — FY26 AR.
  • Extended IP runway: EPO intention to grant (to May 2039) and US Notice of Allowance on drug substance (to May 2040) — July 2026 releases.
  • Experienced commercial leadership: Chairman and CEO collectively launched >30 dermatology products and participated in the Medicis (US$2.6bn) and Anacor (US$5.2bn) exits — FY26 AR.
  • Improving cash burn: Q4 FY26 operating outflow A$10.6M vs A$28.4M in Q4 FY25 — quarterly 4Cs.

Weaknesses

  • Low net price realisation: FY26 average GTN 22%; Q3 FY26 trough of 18% — FY26 AR, Q3 4C.
  • Persistent losses: FY26 net loss A$69.8M on A$33.8M revenue (net margin -206%); accumulated losses A$247.0M — FY26 AR.
  • Going-concern material uncertainty in FY26 accounts, absent in FY25 — FY26 AR Note 2.
  • Single-product, single-source dependency: 98% of revenue from Sofdra; API solely from Kaken until Piramal onboarding (2028) — FY26 AR.
  • Governance shortfalls: executive chair, no majority of clearly independent directors, 73.64% vote against FY25 remuneration report, erroneous share issue to CEO, NED fee overpayment — FY25/FY26 ARs.
  • Inventory-heavy balance sheet: A$31.4M inventory (86% of cash) with A$1.35M obsolescence provision for API nearing expiry — FY26 AR Note 6.
  • Incentive design anchored on gross revenue (US$45M/US$100M gross hurdles vested while net revenue was ~A$33M) — FY26 remuneration report.

Opportunities

  • GTN uplift to 30–40%: at FY26 gross sales of A$152.8M, each 1 percentage point of GTN ≈ A$1.5M of net revenue (derived); reaching 30% would have added ~A$12M to FY26 revenue.
  • COGS reduction: Piramal expected to cut long-term COGS by 25–40% and mitigate tariffs via US site — FY26 AR.
  • Platform leverage: acquiring/in-licensing additional dermatology products to run through the fulfilment platform and sales force — FY26 AR strategy.
  • Ex-US licensing: rights to sublicense outside Asia; European patent supports partnering — FY26 AR.
  • Strategic exit: company cites inbound licensing and acquisition interest; precedent of Dermavant/Organon — FY26 AR.
  • Operating leverage from resized sales force: 39 territories generated ~90% of prescriptions — FY26 AR.

Threats

  • Tariffs: 15% tariff on imports from 29 Sep 2026 (~US$10/bottle) — FY26 AR.
  • US drug-pricing policy: MFN proposals and the February 2026 pricing announcement — ASX releases May 2025, Feb 2026.
  • Dilution / financing risk: A$45M raised at A$0.06 (45.5% discount) in Feb 2026; 840.7M options and 96.2M performance rights outstanding — FY26 AR.
  • Debt covenants: Kreos facility secured on all assets with minimum-cash covenant — FY26 AR Note 2; Kreos release.
  • Competitive response: Qbrexza (Journey Medical) promotion and Botox entrenchment — Journey filings.
  • Board spill risk: second strike at 2026 AGM would trigger a spill resolution — Corporations Act two-strikes rule; FY26 AR.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025 (approx.)A$40M institutional placement to accelerate Sofdra commercialisation, citing >1,500 prescribers and 100% eligible-patient refills in March 2025–
May 2025Response to proposed US "most favoured nation" pricing order — Sofdra sold only in the US, impact considered unlikelyPolicy risk management
23 May 2025Co-founder Matthew Callahan resigns as Executive DirectorFounder exit
10 Jun 2025Kreos US$30M facility signed; US$20M drawn; shares rose ~7%Non-dilutive capital; adds secured debt and covenants
Jul 2025JAAD publishes Phase 3 CARDIGAN dataMedical credibility
28 Jul 2025Q4 FY25: TRx +324% QoQ to 13,647; gross sales A$20.4M; net A$4.3M; unique prescribers 2,316Launch inflection
Aug 2025Ecclock approved in South Korea (Dongwha)Ex-US validation
25 Aug 2025Dr Patricia Walker appointed NEDAdds dermatology/clinical expertise
29 Aug 2025FY25 results: revenue A$5.76M, net loss A$86.4MPeak loss year
Oct 2025Sales force reaches 50; Andrew Bickley Company SecretaryCommercial scale-up
20 Oct 2025Q1 FY26: TRx +50% to 20,418; net revenue +65% to A$7.1M; operating outflow -54% to A$13.1MStrong quarter
Oct 2025CEO presents at Canaccord healthcare conference (Noosa) and roadshowInvestor outreach
Nov 2025 (AGM)73.64% vote against remuneration report — first strikeGovernance warning
30 Dec 2025Cancellation of 6.93M shares erroneously issued to the CEOControl weakness
Jan 2026Ecclock launches in South KoreaMinor royalty contribution
27 Jan 2026Q2 FY26: TRx +24%; net revenue +28% to A$9.1M; cash A$31.5M; undrawn debt A$14.9M; HCP survey 90% expect to increase prescribingMomentum, but cash falling
13 Feb 2026Trading halt; statement responding to US pharmaceutical pricing announcementPre-raise; share price ~A$0.11
17 Feb 2026A$45M raise at A$0.06 (45.5% discount) with 1:1 options; shares fell ~41%Major dilution; sentiment reset
27 Feb 20261H FY26 results: revenue A$16.5M; loss A$33.2MHalf-year statutory confirmation
30 Mar 2026API agreement with Kaken renegotiated; ~A$15M purchases deferredCash relief
1 Apr 2026EGM approves tranche 2, SPP and optionsFunding completed
15–16 Apr 2026Term sheet with Piramal as second API supplier; shares +8%COGS/tariff mitigation
Apr 2026US announces intended pharmaceutical tariffsNew cost headwind
29 Apr 2026Q3 FY26: TRx +5% to 26,684; GTN fell to 18% on deductible reset; net revenue A$6.9M; outflow A$23.3M incl. A$9.7M APISeasonal dip; shares around A$0.02
3 May 2026Paul Seaback promoted to COOOperational leadership
6–7 Jul 2026EPO intention to grant applicator patent; shares +13.6%IP extension; Europe optionality
12–13 Jul 2026US Notice of Allowance on drug-substance crystalline formIP extension to 2040
27 Jul 2026Q4 FY26: TRx +25% to 33,358; record June 12,895; net revenue +45% to A$10.1M; outflow A$10.6M; cash A$36.6MBest quarter to date
31 Jul 2026Sales force reduced 50→39 (layoff of 11 territories)~12% opex saving
26 Aug 2026FY26 results: revenue A$33.8M (+487%); net loss A$69.8M; going-concern material uncertaintyFinancial-risk flag
Aug–Sep 2026Share price drifts to A$0.018–0.021; 52-week range A$0.018–0.18Market capitalisation ~A$50–57M
29 Sep 202615% US tariff on Sofdra imports begins (~US$10/bottle)Margin headwind
1 Oct 2026Kreos Tranche B availability window closesDrawdown status undisclosed

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Income Statement: Revenue & Gross Profit: Revenue rose from AUD 0 Mn in FY2022 to AUD 33.8 Mn in FY2026.
Botanix Pharmaceuticals Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue00.10.65.833.8
Gross profit (revenue less materials;)——0.62.319.5
Product sales and marketing expense——038.552

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.